HEPION PHARMACEUTICALS, INC. Net Change in Cash
HEPION PHARMACEUTICALS, INC. (HEPA) reported Net Change in Cash of -$199.44 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-13
- HEPION PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $774.52K, a 81.47% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $4.18M.
- HEPION PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$1.68M.
- HEPION PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$8.20M.
- HEPION PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $1.42M.
- HEPION PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$14.38M.
- HEPION PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$36.40M.
- HEPION PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$40.16M, a 179.33% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$199.44K 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | $774.52K 10-Q · filed 2026-05-14 | ||||
| 2025-12-31 | $1.42M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $1.91M 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $2.52M 10-Q · filed 2026-08-13 | ||||
| 2025-03-31 | $4.18M 10-Q · filed 2026-05-14 | ||||
| 2024-12-31 | -$14.38M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | -$13.29M 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | -$12.67M 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | -$1.68M 10-Q · filed 2025-05-19 | ||||
| 2023-12-31 | -$36.40M 10-K · filed 2025-04-08 | ||||
| 2023-09-30 | -$31.91M 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | -$20.67M 10-Q · filed 2024-08-13 | -$20.67M 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | -$8.20M 10-Q · filed 2024-05-21 | ||||
| 2022-12-31 | -$40.16M 10-K · filed 2024-04-16 | ||||
| 2022-09-30 | -$32.20M 10-Q · filed 2023-11-20 | ||||
| 2022-06-30 | -$19.64M 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | -$12.13M 10-Q · filed 2023-05-12 | ||||
| 2021-12-31 | $50.62M 10-K · filed 2023-04-10 | ||||
| 2021-09-30 | $58.00M 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | $69.36M 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | $74.72M 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | $26.80M 10-K · filed 2022-04-08 | ||||
| 2020-09-30 | -$211.64K 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | $3.64M 10-Q · filed 2021-08-16 | ||||
| 2020-03-31 | $2.12M 10-Q · filed 2021-05-14 | ||||
| 2019-12-31 | $11.09M 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | $12.03M 10-Q · filed 2020-11-16 | ||||
| 2019-06-30 | $14.32M 10-Q · filed 2020-08-12 | ||||
| 2019-03-31 | -$1.15M 10-Q · filed 2020-06-29 | ||||
| 2018-12-31 | -$3.12M 10-K · filed 2020-05-14 | ||||
| 2018-09-30 | $3.08M 10-Q · filed 2019-11-14 | ||||
| 2018-06-30 | -$3.37M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |